GLG News by Oncologists who Treat RCC (US)

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Microarrays and the fingerprints of cancer

July 10, 2011

How Bright Promise in Cancer Testing Fell Apart | www.nytimes.com

Genetic testing in regards too cancer cells has been a long time projectMicroaaray techniques using more reliable RNA versus DNA patterns will likely lead the wayProteionomic is is yet a further downstream approach to classifying cancer uniqueness

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Profitable palliation of none at all?

July 4, 2011

There is a plethora of new treatments for cancer.Universally new cancer treatments are very expensive.There are as many cancer patients being treated for palliative purposes as cure

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Avastin: a targeted drug without a target?

June 30, 2011

Breast Cancer Patients Plead for Avastin Approval | www.nytimes.com

Targeted cancer therapy is the trend in oncology therapyAvastin is a targeted therapy that has only theory backing up it's mode of actionAvastin has the benefit and drawback of being designated as broadly active yet specific to no cancer!

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

New Agents in Melanoma Show Advances at ASCO

June 9, 2011

Drugs Show Promise Slowing Advanced Melanoma | www.nytimes.com

Data presented a the ASCO meeting showed an overall survival benefit for patients receiving Roche/Genentech's vemurafenib and Bristol-Myers Squibb/s Yervoy (ipilimumab) when these agents were compared to standard of care therapy.

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Tarceva gives more proof: One should know the target for Targeted therapy

June 4, 2011

Roche’s Tarceva Stalls Lung Cancer With Gene Mutation in Late-Stage Study | www.bloomberg.com

So called targeted therapy has been a term coined over the last decade in the approach to treating cancer. A recent Roche study demonstrates almost doubling of disease control when one uses a patient population that has a defined target is treated with the drug Tarceva

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Necessity may be the mother of invention,but the father is profit.

April 16, 2011

Shortage Worsens of Leukemia Drug | online.wsj.com

There is a shortage of many cancer fighting medications, as more and more of the agents used to treat cancer become generic. The problem is both profit and regulation driven.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Long term Revlimid (Celgene) may cause cancer.

December 7, 2010

Celgene shares plummet on Revlimid malignancy data | www.reuters.com

Data presented at the American Society of Hematology Convention suggests the possibility that long term use of Revlimid may be a associated with the development of secondary malignancies.

Jeffrey Bubis, Partner, Hematologist and Medical Oncologist

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Outlook is better for Provenge

November 20, 2010

Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

A Medicare advisory panel gave a lukewarm endorsement to Provenge. Final Medicare opinion is pending.

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Provenge - Do we really have a choice?

November 19, 2010

Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

Provenge has received FDA clearance for the use in hormone resistant prostate cancer, a disease that kills over 30,000 American men each year. The data says this will extend life for several months on the average, but some may achieve surprising results of regression of disease and even years. The cost is rather high, over $90k for the treatment.

Donald Fleming, Director of the Cancer Care Center

Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC. What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Will provenge fall the way of radioimmunotherapy

November 19, 2010

Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

Provenge recently approved for HRPC .Provenge was designed for asymptomatic patients with increasing PSAsProvenge involves referral to a specialized center to perform the procedure

Page : 12345678910Next1 to 10 of 146

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News